← All trials
NCT04597723
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 3, 2022
- Primary completion
- Jan 3, 2023
- Completion date
- May 3, 2023
- First posted
- Oct 22, 2020
- Last posted
- Oct 22, 2020
- Enrollment
- 111
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Selcuk UniversityLead sponsor
- Gazi UniversityStudy chair
- The Scientific and Technological Research Council of TurkeyCollaborator
- Selcuk UniversityStudy chair
- Selcuk UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.